ClinicalTrials.gg
CompletedNCT04772313Updated Jun 27, 2024Results posted

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

A Phase 4 interventional study of Pegloticase and Methotrexate (MTX) in Uncontrolled Gout, sponsored by Amgen. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
13th of 14
11 · median 93
Started
2021
with 1 other
Phase 4
7 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 13th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 12th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

This is a Phase 4, multicenter, open-label trial of pegloticase with methotrexate (MTX) in adult participants with uncontrolled gout who were previously treated with pegloticase without a concomitant immunomodulator and stopped pegloticase due to failure to maintain serum uric acid (sUA) response and/or a clinically mild infusion reaction (IR). Approximately 30 participants will be enrolled. Pegloticase + MTX will be administered for approximately 24 weeks, with an optional extension up to 48 weeks.

The trial design will include 5 distinct components:

  1. Screening Period, lasting up to 42 days;
  2. 6-week MTX Tolerability Assessment Period (hereafter referred to as the MTX Run-in Period);
  3. 24-week Pegloticase + MTX Treatment Period, which will include a Week 24/End of Trial/Early Termination Visit (subjects that end MTX and pegloticase treatment prior to the Week 24 will remain on trial for follow up until the Week 24 visit)
  4. Optional Pegloticase + MTX Extension Period up to 24 weeks
  5. 30-Day Post Treatment Follow -up
Read the detailed description

All participants who meet eligibility criteria at Screening will begin once-weekly subcutaneous (SC) MTX Run-in period. Participants must be able to tolerate MTX at a minimum dose of 15 mg during the 6-week MTX Run-in Period to be eligible to participate in the Pegloticase + MTX Treatment Period.

All participants who meet the inclusion/exclusion criteria and complete the MTX Run-in Period will be considered enrolled participants. During the Pegloticase + MTX Treatment Period, pegloticase 8 mg will be administered IV every 2 weeks and MTX SC weekly.

Two sequential cohorts of participants will be enrolled in this trial. Cohort 1 is targeted to enroll 10 participants who previously failed to maintain sUA response with pegloticase monotherapy and stopped pegloticase treatment without a history of pegloticase-related infusion reaction.

If the safety assessment during Cohort 1 indicates that the pegloticase infusions are well tolerated, then the trial can begin enrolling Cohort 2 for 20 participants who failed to maintain sUA response with pegloticase monotherapy with or without a history of pegloticase-related clinically mild IRs.

Study acquired from Horizon in 2024.

03

Conditions studied

  • Uncontrolled Gout

Browse trials for

Keywords

  • Gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give .
  2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
  3. Adult men or women ≥18 years of age.
  4. Uncontrolled gout, defined by the following criteria:

    • Hyperuricemia during the Screening Period, defined as sUA ≥6 mg/dL, and;
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose or with a to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;
    • Symptoms of gout, including at least 1 of the following:

      • Presence of at least 1 tophus
      • Recurrent flares, defined as 2 or more flares in the 12 months prior to Screening
      • Presence of chronic gouty arthritis
  5. Subject was previously treated with pegloticase without concomitant immunomodulation and stopped pegloticase due to failure to maintain sUA reduction response (had ≥1 sUA >6 mg/dL within 2 weeks post pegloticase infusion) and did not experience an IR (Cohort 1) and/or stopped pegloticase treatment due to pegloticase-related clinically mild IR (Cohort 2).
  6. Subject for whom the last pegloticase infusion occurred >6 months prior to Screening.
  7. Willing to discontinue any oral urate-lowering therapy for at least 7 days prior to Day 1 and remain off other urate-lowering therapy during the Pegloticase + MTX Treatment Period.
  8. Women of (including those with an onset of menopause \<2 years prior to Screening, non-therapy-induced amenorrhea for \<12 months prior to Screening or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum pregnancy tests during Screening:

    Subjects must agree to use 2 reliable forms of during the trial, 1 of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -6 (start of MTX) and continue for 30 days after the last dose of pegloticase, or at least 1 ovulatory cycle after the last dose of MTX (whichever is the longer duration after the last dose of pegloticase). Highly effective contraceptive methods (with a failure rate \<1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner.

  9. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of during the trial, beginning with the initiation of MTX at Week -6 and continuing for at least 3 months after the last dose of MTX.
  10. Able to tolerate MTX at SC doses of at least 15 mg during the MTX Run-in Period, regardless of estimated (eGFR) status.

Exclusion criteria

Exclusion Criteria:

  1. Known history of medically confirmed prior anaphylactic reaction.
  2. Known history of moderate or severe IR (including but not limited to difficulty in breathing, hypotension, generalized urticaria, generalized erythema, angioedema and/or required treatment with IV or epinephrine; or other serious adverse events (SAEs) related to pegloticase or any other pegylated product treatment.
  3. Weight >160 kg (352 pounds) at Screening.
  4. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Week 6 Visit.
  5. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  6. Current or chronic treatment with systemic agents, such as MTX, azathioprine, cyclosporine, leflunomide, cyclophosphamide or mycophenolate mofetil.
  7. Current treatment with prednisone >10 mg/day or equivalent dose of another corticosteroid on a chronic basis (defined as 3 months or longer).
  8. Known history of any solid organ transplant surgery requiring maintenance immunosuppressive therapy.
  9. Known history of virus surface antigen positivity or hepatitis B DNA positivity, unless treated, viral load is negative and no chronic or active infection confirmed by hepatitis B virus serology.
  10. Known history of virus RNA positivity, unless treated and viral load is negative.
  11. Known history of positivity.
  12. glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at the Screening Visit).
  13. Severe chronic renal impairment ( \<30 mL/min/1.73 m\^2) at the Screening Visit based on 4 variable Modification of Diet in Renal Disease [MDRD] formula or currently on dialysis.
  14. Non-compensated congestive heart failure, hospitalization for congestive heart failure or treatment for acute coronary syndrome (myocardial infarction or unstable angina) within 3 months of the Screening Visit, current uncontrolled arrhythmia or current uncontrolled blood pressure (>160/100 mm Hg) prior to Week -6.
  15. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of , as determined by the Investigator.
  16. Prior treatment with another recombinant uricase (rasburicase) or concomitant therapy with a PEG-conjugated drug.
  17. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
  18. to MTX treatment or MTX treatment considered inappropriate.
  19. Known intolerance to MTX.
  20. Receipt of an drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -6 or plan to take an investigational drug during the trial.
  21. Current liver disease, as determined by (ALT) or aspartate transaminase (AST) >1.25 × (ULN) or albumin \<lower limit of normal at the Screening Visit.
  22. Currently receiving systemic or radiologic treatment for ongoing cancer, excluding nonmelanoma skin cancer.
  23. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
  24. White blood cell count \<4.0 × 10\^9/L, hematocrit \<32% or count \<75 × 10\^9/L.
  25. Diagnosis of osteomyelitis.
  26. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
  27. Unsuitable candidate for the trial (e.g., cognitive impairment), based on the opinion of the Investigator, such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the trial.
  28. Alcohol use in excess of 3 alcoholic beverages per week.
  29. A known intolerance to all protocol standard gout flare prophylaxis regimen (i.e., unable to tolerate any of the following 3 agents: colchicine,nonsteroidal anti-inflammatory drugs (NSAIDs) or low- dose prednisone (≤10 mg/day).
  30. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest x-ray may be performed during Screening.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Pegloticase plus Methotrexate (MTX)

    Pegloticase (8 mg) intravenous (IV) every two weeks. Methotrexate (15 or 25 mg weekly) SC.

    Biological: Pegloticase · Drug: Methotrexate (MTX)

Interventions

  • BiologicalPegloticase

    Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.

  • Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

    An sUA responder is defined as a participant achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 21, 22, 23 and 24).

    Time frame: Month 6

Secondary outcomes

  1. Percentage of sUA Responders (sUA < 6 mg/dL) During Month 3

    An sUA responder is defined as a participant achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 3 (Weeks 10 to 14).

    Time frame: Month 3

  2. Percentage of Participants Who Experienced Any of the Following Events From Day 1 to Week 24: Infusion Reaction (IR) Leading to Discontinuation of Treatment, Anaphylaxis or Meeting Individual Participant sUA Discontinuation Criteria

    Individual participant sUA discontinuation criteria are met when the lowest available interim sUA value after the pegloticase infusion at Week 2, 4, 6, 8, 10 or 12 is less than a 50% reduction from the highest sUA value measured between Screening and pre-infusion on Day 1.

    Time frame: Day1 to Week 24

  3. Mean Change From Baseline in Urate Deposition Volume Measured by Dual Energy Computed Tomography (DECT) to Week 24

    DECT scans measure urate deposition volume. DECT scans at Week 24 were taken for hands, foot/ankle, and knees.

    Time frame: Baseline to Week 24

  4. Mean Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 14 and 24

    HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing grooming, arising, eating, walking, hygiene, reach, grip, usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability.

    Time frame: Baseline, Week 14, Week 24

  5. Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Score at Weeks 14 and 24

    The HAQ pain scale asks participants to record how much pain they have had in the past week on a scale of 0-100 where zero represents no pain and 100 represents severe pain.

    Time frame: Baseline, Week 14, Week 24

  6. Mean Change From Baseline in HAQ Health Score at Weeks 14 and 24

    The HAQ health scale is a measure of overall health. Participants are asked to rate how well they are doing on a scale of 0 to 100, where zero represents very well and 100 represents very poor health.

    Time frame: Baseline, Week 14, Week 24

07

Results

Posted Oct 10, 2023

Participant flow

MTX Run-in Period
Participant flow — MTX Run-in Period
MilestonePegloticase Plus Methotrexate
Started13
Completed11
Not completed2
Pegloticase + MTX Treatment Period
Participant flow — Pegloticase + MTX Treatment Period
MilestonePegloticase Plus Methotrexate
Started11
Completed5
Not completed6
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject3
Pegloticase + MTX Extension Period
Participant flow — Pegloticase + MTX Extension Period
MilestonePegloticase Plus Methotrexate
Started1
Completed1
Not completed0

Outcome measures

PrimaryPercentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

An sUA responder is defined as a participant achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 21, 22, 23 and 24).

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
percentage of participantsPegloticase Plus Methotrexate
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 69.1 (0.2 to 41.3)
SecondaryPercentage of sUA Responders (sUA < 6 mg/dL) During Month 3

An sUA responder is defined as a participant achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 3 (Weeks 10 to 14).

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of sUA Responders (sUA < 6 mg/dL) During Month 3
percentage of participantsPegloticase Plus Methotrexate
Percentage of sUA Responders (sUA < 6 mg/dL) During Month 39.1 (0.2 to 41.3)
SecondaryPercentage of Participants Who Experienced Any of the Following Events From Day 1 to Week 24: Infusion Reaction (IR) Leading to Discontinuation of Treatment, Anaphylaxis or Meeting Individual Participant sUA Discontinuation Criteria

Individual participant sUA discontinuation criteria are met when the lowest available interim sUA value after the pegloticase infusion at Week 2, 4, 6, 8, 10 or 12 is less than a 50% reduction from the highest sUA value measured between Screening and pre-infusion on Day 1.

Time frame:
Day1 to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Any of the Following Events From Day 1 to Week 24: Infusion Reaction (IR) Leading to Discontinuation of Treatment, Anaphylaxis or Meeting Individual Participant sUA Discontinuation Criteria
percentage of participantsPegloticase Plus Methotrexate
Percentage of Participants Who Experienced Any of the Following Events From Day 1 to Week 24: Infusion Reaction (IR) Leading to Discontinuation of Treatment, Anaphylaxis or Meeting Individual Participant sUA Discontinuation Criteria81.8 (48.2 to 97.7)
SecondaryMean Change From Baseline in Urate Deposition Volume Measured by Dual Energy Computed Tomography (DECT) to Week 24

DECT scans measure urate deposition volume. DECT scans at Week 24 were taken for hands, foot/ankle, and knees.

Time frame:
Baseline to Week 24
Reported as:
Mean · cm^3
Mean Change From Baseline in Urate Deposition Volume Measured by Dual Energy Computed Tomography (DECT) to Week 24
cm^3Pegloticase Plus Methotrexate
Change in Total Urate Volume of Hands-0.073 ± 0.1270
Change in Total Urate Volume of Foot/Ankle-1.540 ± 1.7545
Change in Total Urate Volume of Knees-1.207 ± 0.9073
SecondaryMean Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 14 and 24

HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing grooming, arising, eating, walking, hygiene, reach, grip, usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability.

Time frame:
Baseline, Week 14, Week 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 14 and 24
score on a scalePegloticase Plus Methotrexate
Change at Week 140.25 ± 0.617
Change at Week 240.10 ± 0.163
SecondaryMean Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Score at Weeks 14 and 24

The HAQ pain scale asks participants to record how much pain they have had in the past week on a scale of 0-100 where zero represents no pain and 100 represents severe pain.

Time frame:
Baseline, Week 14, Week 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Score at Weeks 14 and 24
score on a scalePegloticase Plus Methotrexate
Change at Week 1410.67 ± 19.664
Change at Week 24-4.00 ± 15.166
SecondaryMean Change From Baseline in HAQ Health Score at Weeks 14 and 24

The HAQ health scale is a measure of overall health. Participants are asked to rate how well they are doing on a scale of 0 to 100, where zero represents very well and 100 represents very poor health.

Time frame:
Baseline, Week 14, Week 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in HAQ Health Score at Weeks 14 and 24
score on a scalePegloticase Plus Methotrexate
Change at Week 148.00 ± 45.343
Change at Week 24-11.40 ± 24.389

Adverse events

Collected over From enrollment (all-cause mortality) or first dose of study drug (adverse events) up to Week 48 + 30 days (±3 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MTX Run-In Period0/13 (0%)1/13 (7.7%)7/13 (53.8%)
Pegloticase + MTX Treatment Period0/11 (0%)1/11 (9.1%)8/11 (72.7%)
Most frequent serious events
Most frequent serious events
EventMTX Run-In PeriodPegloticase + MTX Treatment Period
Septic shockInfections and infestations0/131/11
Perineal abscessInfections and infestations1/130/11
Most frequent other events
Showing 10 of 29
Most frequent other events
EventMTX Run-In PeriodPegloticase + MTX Treatment Period
GoutMetabolism and nutrition disorders6/137/11
Infusion related reactionInjury, poisoning and procedural complications0/132/11
ArthralgiaMusculoskeletal and connective tissue disorders1/132/11
Pain in extremityMusculoskeletal and connective tissue disorders0/132/11
FatigueGeneral disorders2/130/11
CataractEye disorders0/131/11
DiarrhoeaGastrointestinal disorders0/131/11
NauseaGastrointestinal disorders0/131/11
Upper respiratory tract infectionInfections and infestations0/131/11
Muscle strainInjury, poisoning and procedural complications0/131/11

Baseline characteristics

Intent to Treat (ITT) population

Age, Continuous
Age, Continuous(years)Pegloticase Plus Methotrexate
Mean58.6 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase Plus Methotrexate
Female1
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase Plus Methotrexate
Hispanic or Latino3
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegloticase Plus Methotrexate
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White7
More than one race1
Unknown or Not Reported1
08

Study locations

15 sites
  • University of Alabama at Birmingham (UAB) - Center for Education & Research on Therapeutics of Musculoskeletal Disorders
    Birmingham, Alabama 35294-0002, United States
  • Arizona Arthritis and Rheumatology Associates
    Flagstaff, Arizona 86001, United States
  • Arizona Arthritis and Rheumatology Associates
    Glendale, Arizona 85306, United States
  • Arizona Arthritis and Rheumatology Associates
    Mesa, Arizona 85210, United States
  • East Bay Rheumatology Medical Group
    San Leandro, California 94578, United States
  • Providence St. John's Health Clinic
    Santa Monica, California 90404, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045-2536, United States
  • Life Clinical Trials
    Margate, Florida 33063, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • Napa Research
    Pompano Beach, Florida 33046, United States
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Western Washington Arthritis Clinic
    Bothell, Washington 98021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2022, 17 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion.

Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Feb 26, 2021
StartActual
Mar 8, 2021
Primary completionActual
Aug 23, 2022
CompletionActual
Apr 24, 2023
Results first posted
Oct 10, 2023
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04772313
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Mar 8, 2021
Primary completion
Aug 23, 2022
Completion
Apr 24, 2023
Results posted
Oct 10, 2023
Last update
Jun 27, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion